All In Biotech

Drug Trial Radar · NCT07047144

A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA)

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Sep 15, 2025

Primary completion

Nov 2028

Study completion Mar 2029

Sponsor

Lead sponsor
Scholar Rock, Inc.Industry
Sponsor type
Industry
First posted
Jul 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This double-blind, Phase 2, multiple-dose study will be conducted to evaluate the PK/PD, efficacy, safety, and tolerability of apitegromab in subjects \<2 years old with 5q autosomal recessive SMA who have delayed motor milestones for their age attributed to SMA at the discretion of the Investigator or a Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score \<55.

Conditions

  • Spinal Muscular Atrophy
  • SMA
  • Spinal Muscular Atrophy Type 2
  • Spinal Muscular Atrophy Type 3
  • Neuromuscular Manifestations
  • Anti-myostatin

Interventions

  • ApitegromabDrug

    Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 will be administered every 4 weeks by intravenous (IV) infusion.

  • NusinersenDrug

    Nusinersen is a current standard-of-care SMN therapy that targets the SMN2 gene. It will be administered intrathecally per the prescribing information.

  • RisdiplamDrug

    Risdiplam is a current standard-of-care SMN therapy that targets the SMN2 gene. It will be administered orally per the prescribing information.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the PK of apitegromab in subjects <2 years old with SMATime frame: 52 Weeks
  2. Evaluate the PD of apitegromab in subjects <2 years old with SMATime frame: 52 Weeks
  3. Evaluate the motor function outcomes (ie, efficacy) due to apitegromab treatmentTime frame: 48 Weeks

Locations

23 sites in 7 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona · Recruiting

  • Children's Hospital of Orange County (CHOC)

    Orange, California · Recruiting

  • Stanford Neuroscience Health Center (SNHC)

    Palo Alto, California · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • Children's Healthcare of Atlanta

    Atlanta, Georgia · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Helen DeVos Children's Hospital at Spectrum Health

    Grand Rapids, Michigan · Recruiting

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Neurology Rare Disease Center

    Flower Mound, Texas · Recruiting

  • Cook Children's Medical Center

    Fort Worth, Texas · Recruiting

  • Texas Children's Hospital (TCH)-Clinical Care Center (CCC)

    Houston, Texas · Recruiting

  • UZ Leuven - Campus Gasthuisberg

    Leuven, Belgium · Recruiting

  • CHR Citadelle

    Liège, Belgium · Recruiting

  • UZ Gent

    Ghent, East-Flanders, Belgium · Recruiting

  • Hopital Trousseau - I-Motion

    Paris, France · Recruiting

  • Fondazione I.R.C.C.S. - Istituto Neurologico Carlo Besta

    Milan, Italy · Recruiting

  • Centro Clinico NeMO Milano - Fondazione Serena Onlus

    Milan, Italy · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Rome, Italy · Recruiting

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands · Recruiting

  • Hospital Sant Joan de Déu Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Universitari i Politecnico La Fecnic La Fe

    Valencia, Spain · Recruiting

  • Leeds General Infirmary Children's Research Department

    Leeds, West Yorkshire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.